I know, hence it will help formulate part of MSB's argument about why they cannot conduct a RCT, since it will be unethical. But if you remember, the FDA still recommended a RCT as part of the CRL in spite of what was argued as part of ODAC.
And as Lopez mentioned, the FDA also requested a lot of data, which will help MSB's attempt to bypass the need for a RCT. So in the end it will come down to whether the FDA will require a RCT or whether MSB have done enough to bypass this requirement.
Or are you saying that an RCT is irrelevant?
I know, hence it will help formulate part of MSB's argument...
-
- There are more pages in this discussion • 858 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |